Centiva Capital, LP Maxcyte, Inc. Transaction History
Centiva Capital, LP
- $3.13 Billion
- Q1 2025
A detailed history of Centiva Capital, LP transactions in Maxcyte, Inc. stock. As of the latest transaction made, Centiva Capital, LP holds 31,518 shares of MXCT stock, worth $70,285. This represents 0.0% of its overall portfolio holdings.
Number of Shares
31,518
Previous 24,993
26.11%
Holding current value
$70,285
Previous $103,000
16.5%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding MXCT
# of Institutions
119Shares Held
73.1MCall Options Held
0Put Options Held
0-
Cadian Capital Management, LP New York, NY10MShares$22.4 Million1.17% of portfolio
-
Black Rock Inc. New York, NY8.14MShares$18.2 Million0.0% of portfolio
-
Morgan Stanley New York, NY7MShares$15.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.57MShares$12.4 Million0.0% of portfolio
-
Vitruvian Partners LLP5.04MShares$11.2 Million13.13% of portfolio
About MAXCYTE, INC.
- Ticker MXCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 101,724,000
- Market Cap $227M
- Description
- MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expr...